RA0752

antibody from Oursmab

Targeting: TNFRSF10B CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0752

Provider

Oursmab

Product name

Lexatumumab (Biosimilar Reference Antibody) (TNFRSF10B)

Antibody type

Monoclonal

Description

Lexatumumab (also known as HGS-ETR2) is a fully human monoclonal antibody that specifically targets and activates TRAIL receptor 2 (TRAIL-R2, also known as DR5 or TNFRSF10B), a member of the tumor necrosis factor (TNF) receptor superfamily. As an agonist antibody, it binds to DR5 and mimics the action of the natural ligand TRAIL (TNF-related apoptosis-inducing ligand), thereby inducing apoptosis (programmed cell death) in cancer cells that express the receptor. It was developed as a potential therapeutic agent for the treatment of various advanced solid tumors and hematologic malignancies, based on the premise of selectively triggering cell death in tumors while sparing most normal cells.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.